ACTR-70. IMPACT OF BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND POOR PERFORMANCE STATUS

Clinical trials have showed that bevacizumab is beneficial for patients with recurrent glioblastoma and partially effective against newly diagnosed glioblastoma. However, glioblastoma patients with poor performance status (PS) were excluded from these clinical trials, and the efficacy of bevacizumab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Furuse, Motomasa, Kawabata, Shinji, Ikeda, Naokado, Nonoguchi, Naosuke, Tamura, Yoji, Kajimoto, Yoshinaga, Miyatake, Shin-Ichi, Kuroiwa, Toshihiko
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693094/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.057
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars